Search hospitals > New York > Albany
New York Oncology Hematology, PC
Claim this profileAlbany, New York 12206
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
185 reported clinical trials
5 medical researchers
Summary
New York Oncology Hematology, PC is a medical facility located in Albany, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and other specialties. New York Oncology Hematology, PC is involved with conducting 185 clinical trials across 172 conditions. There are 5 research doctors associated with this hospital, such as Karen Tedesco, Rahul Ravilla, MD, Mihir Raval, MD, and Lawrence E. Garbo, MD.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Karen TedescoUSO - New York Oncology Hematology8 years of reported clinical research
Studies Breast Cancer
6 reported clinical trials
14 drugs studied
Rahul Ravilla, MDNew York Oncology Hematology, P.C.4 years of reported clinical research
Studies Prostate Cancer
Studies Bladder Cancer
4 reported clinical trials
9 drugs studied
Mihir Raval, MDNew York Oncology Hematology, P.C.6 years of reported clinical research
Studies Multiple Myeloma
Studies Follicular Lymphoma
4 reported clinical trials
12 drugs studied
Lawrence E. Garbo, MDNew York Oncology Hematology, P.C.2 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
2 reported clinical trials
4 drugs studied
Clinical Trials running at New York Oncology Hematology, PC
Lung Cancer
Breast Cancer
Non-Hodgkin's Lymphoma
Cancer
Follicular Lymphoma
Colorectal Cancer
Ovarian Cancer
Diffuse Large B-Cell Lymphoma
Melanoma
Non-Small Cell Lung Cancer
MK-1084 + Pembrolizumab
for Lung Cancer
Researchers want to learn if the study medicines MK-1084 and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. MK-1084 is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive MK-1084 with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.
Recruiting2 awards Phase 31 criteria
V940 + Pembrolizumab
for Lung Cancer
This trial is testing a new treatment combination of V940 and pembrolizumab in patients who have had surgery to remove Stage II, IIIA, or IIIB non-small cell lung cancer. The goal is to see if this new combination can help prevent the cancer from coming back. V940 and pembrolizumab work together to help the immune system find and destroy any leftover cancer cells.
Recruiting1 award Phase 37 criteria
MK-1084 + Pembrolizumab
for Lung Cancer
This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of MK-1084 and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of MK-1084 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS).
Recruiting1 award Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at New York Oncology Hematology, PC?
New York Oncology Hematology, PC is a medical facility located in Albany, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and other specialties. New York Oncology Hematology, PC is involved with conducting 185 clinical trials across 172 conditions. There are 5 research doctors associated with this hospital, such as Karen Tedesco, Rahul Ravilla, MD, Mihir Raval, MD, and Lawrence E. Garbo, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.